Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Xueke Jia"'
Publikováno v:
The Journal of craniofacial surgery.
This study aimed to introduce the clinical application of the CAD/CAM-guided modified Dautrey's procedure in recurrent anterior temporomandibular joint luxation and evaluate its clinical effects. Four selected patients were treated by the CAD/CAM-gui
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ac973fd09bd20187a71033a1bc699aa
https://pubmed.ncbi.nlm.nih.gov/36176036
https://pubmed.ncbi.nlm.nih.gov/36176036
Publikováno v:
Fuel. 252:228-237
The Pt@FGS/JP-10 nanofluids (0.1 wt% for Pt) were successfully prepared by two consecutive steps: loading Pt nanoparticles on the functionalized graphene sheets (FGS) grafted octadecylamine (ODA) via wet chemical method, following by dispersing it in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb4bf87bbd44d3b256b09c97f4f2b018
https://doi.org/10.1016/j.fuel.2019.04.119
https://doi.org/10.1016/j.fuel.2019.04.119
Publikováno v:
Energy & Fuels. 31:8023-8035
High-pressure thermal decomposition of tetrahydrotricyclopentadiene (THTCPD) and binary high-density hydrocarbon fuels of JP-10/THTCPD were investigated at 500–660 °C and 4.0 MPa in an electrically heated tubular reactor. The decomposition of THTC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3563a03f03d38f94f24aad0544558d61
https://doi.org/10.1021/acs.energyfuels.7b01128
https://doi.org/10.1021/acs.energyfuels.7b01128
Autor:
Aiqin Gu, Lieming Ding, Yinxiang Wang, Xingsheng Hu, Jiewen Peng, Li Zhang, Shucai Zhang, Changxuan You, Yiping Zhang, Shunchang Jiao, Baohui Han, Meina Wu, Junye Wang, K. Ma, Kejing Ying, Jintao He, Xueke Jia, Yan Sun, Fenlai Tan, Chang li Wang
Publikováno v:
Lung Cancer. 86:207-212
Background The phase 3 ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients, and this led to the approval of icotinib for NSCLC by the China F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdcacf5b8ee522878b24e3f2a6f2a2ab
https://doi.org/10.1016/j.lungcan.2014.08.014
https://doi.org/10.1016/j.lungcan.2014.08.014
Autor:
Yipei Jing, Xueke Jiang, Li Lei, Meixi Peng, Jun Ren, Qiaoling Xiao, Yao Tao, Yonghong Tao, Junpeng Huang, Lu Wang, Yuting Tang, Zailin Yang, Zesong Yang, Ling Zhang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-23 (2021)
Abstract Background Acute myeloid leukemia (AML) with mutated nucleophosmin (NPM1), which displays a distinct long noncoding RNA (lncRNA) expression profile, has been defined as a unique subgroup in the new classification of myeloid neoplasms. Howeve
Externí odkaz:
https://doaj.org/article/9adc295464fd44b395e9df2ba3712621
Autor:
Qiaoling Xiao, Li Lei, Jun Ren, Meixi Peng, Yipei Jing, Xueke Jiang, Junpeng Huang, Yonghong Tao, Can Lin, Jing Yang, Minghui Sun, Lisha Tang, Xingyu Wei, Zailin Yang, Ling Zhang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Acute myeloid leukemia (AML) with nucleophosmin 1 (NPM1) mutations exhibits distinct biological and clinical features, accounting for approximately one-third of AML. Recently, the N6-methyladenosine (m6A) RNA modification has emerged as a new epigene
Externí odkaz:
https://doaj.org/article/1e59047ba36441a1bb95a3ce368cc176
Autor:
Meixi Peng, Jun Ren, Yipei Jing, Xueke Jiang, Qiaoling Xiao, Junpeng Huang, Yonghong Tao, Li Lei, Xin Wang, Zailin Yang, Zesong Yang, Qian Zhan, Can Lin, Guoxiang Jin, Xian Zhang, Ling Zhang
Publikováno v:
Journal of Extracellular Vesicles, Vol 10, Iss 13, Pp n/a-n/a (2021)
Abstract Acute myeloid leukaemia (AML) carrying nucleophosmin (NPM1) mutations has been defined as a distinct entity of acute leukaemia. Despite remarkable improvements in diagnosis and treatment, the long‐term outcomes for this entity remain unsat
Externí odkaz:
https://doaj.org/article/cb84c96563384f6794e5ae30574aab8d
Autor:
Yinxiang Wang, Jiang Wan, Junye Wang, K. Ma, Meina Wu, Shunchang Jiao, Li Zhang, Lieming Ding, Jiewen Peng, Aiqin Gu, Changxuan You, Changli Wang, Kejing Ying, Haijiao Shen, Shucai Zhang, Yiping Zhang, Yan Sun, Jintao He, Xueke Jia, Fenlai Tan
Publikováno v:
Journal of Clinical Oncology. 31:e19161-e19161
e19161 Background: The phase III ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS), based on which icotinib was approved by State Food and Drug Administration of China. We conducted a sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d47cc48f8f8cec831edcf0db6410ce4
https://doi.org/10.1200/jco.2013.31.15_suppl.e19161
https://doi.org/10.1200/jco.2013.31.15_suppl.e19161
Publikováno v:
Energy & Fuels; 8/17/2017, Vol. 31 Issue 8, p8023-8035, 13p